Combinatorial Treatment of "Armed" Oncolytic Adenovirus Expressing Checkpoint Inhibitor and Cytokine with Chimeric Antigen Receptor T-Cells Leads to Superior Anti-Tumor Effects in Head and Neck Cancer

被引：0
|
作者：
Shaw, Amanda Rosewell [1 ]
Porter, Caroline [1 ]
Watanabe, Norihiro [1 ]
Tanoue, Kiyonori [1 ]
Brenner, Malcolm [1 ]
Suzuki, Masataka [1 ]
机构：
[1] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
来源：
MOLECULAR THERAPY | 2017年 / 25卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
12
引用
收藏
页码：6 / 7
页数：2
相关论文
共 28 条
  • [21] Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells
    Xing, Haiyan
    Yang, Xue
    Xu, Yingxi
    Tang, Kejing
    Tian, Zheng
    Chen, Zhaoqi
    Zhang, Yu
    Xue, Zhenya
    Rao, Qing
    Wang, Min
    Wang, Jianxiang
    CYTOTHERAPY, 2021, 23 (09) : 810 - 819
  • [22] Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer
    van Schalkwyk, May C. I.
    Papa, Sophie E.
    Jeannon, Jean-Pierre
    Urbano, Teresa Guerrero
    Spicer, James F.
    Maher, John
    HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2013, 24 (03) : 134 - 142
  • [23] Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)
    Galetto, Roman
    Chion-Sotinel, Isabelle
    Gouble, Agnes
    Smith, Julianne
    BLOOD, 2015, 126 (23)
  • [24] Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects
    Sakemura, Reona
    Eckert, Elizabeth C.
    Crotts, Sydney B.
    Pham, Linh
    Siegler, Elizabeth L.
    Cox, Michelle J.
    Tapper, Erin E.
    Hefazi, Mehrdad
    Roman, Claudia Manriquez
    Schick, Kendall J.
    Can, Ismail
    Bezerra, Evandro D.
    Fonkoua, Lionel Kankeu
    Horvei, Paulina
    Ruff, Michael W.
    Slager, Susan L.
    Parikh, Sameer A.
    Kay, Neil E.
    Peng, Kah-Whye
    Russell, Stephen J.
    Kenderian, Saad S.
    BLOOD, 2020, 136
  • [25] Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models
    Sakemura, Reona
    Cox, Michelle J.
    Siegler, Elizabeth L.
    Tapper, Erin E.
    Nevala, Wendy K.
    Hefazi, Mehrdad
    Roman, Claudia Manriquez
    Schick, Kendall J.
    Can, Ismail
    Bezerra, Evandro D.
    Fonkoua, Lionel Kankeu
    Horvei, Paulina
    Ruff, Michael W.
    Mouritsen, Lars
    Foulks, Jason M.
    Warner, Steven L.
    Ding, Wei
    Slager, Susan L.
    Parikh, Sameer A.
    Kay, Neil E.
    Kenderian, Saad S.
    BLOOD, 2020, 136
  • [26] T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
    Sailer, Nadja
    Fetzer, Ina
    Salvermoser, Melanie
    Braun, Monika
    Brechtefeld, Doris
    Krendl, Christian
    Geiger, Christiane
    Mutze, Kathrin
    Noessner, Elfriede
    Schendel, Dolores
    Buerdek, Maja
    Wilde, Susanne
    Sommermeyer, Daniel
    CANCERS, 2022, 14 (08)
  • [27] Direct Integration of Anti-CD19 Chimeric-Antigen-Receptor (CAR) T Cells Early after Post-Transplantation Cyclophosphamide (PTCy) in Murine MHC-Haploidentical Hematopoietic Cell Transplantation (HCT) Exerts Anti-Tumor Effects without Causing Graft-Versus-Host Disease (GVHD)
    Patterson, Michael T.
    Mendu, Suresh K.
    Eckhaus, Michael A.
    Fletcher, Rochelle E.
    Nunes, Natalia S.
    Ishii, Kazusa
    Qin, Haiying
    Fry, Terry J.
    Kanakry, Christopher G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S170 - S171
  • [28] Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden
    Mu, Juan
    Deng, Haobin
    Lyu, Cuicui
    Yuan, Jijun
    Li, Qing
    Wang, Jia
    Jiang, Yanyu
    Deng, Qi
    Shen, Jichun
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (02) : 275 - 284
123